Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/20/2024 | $4.00 | Buy | Craig Hallum |
| 11/2/2022 | $5.00 | Outperform | Robert W. Baird |
| 6/14/2022 | $4.00 | Buy | B. Riley Securities |
| 8/19/2021 | $8.00 | Outperform | Noble Capital Markets |
SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)
SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)
SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)
$30 Million Upfront With Up to an Additional $36 Million of Aggregate Gross Proceeds Upon the Exercise in Full of Clinical Milestone-linked Common Warrants Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the first closing of its previously announced registered direct offering for the purchase and sale of up to an aggregate of 39,473,688 of Lineage's common shares and accompanying warrants (the "common warrants") to purchase an aggregate of up to 39,473,688 of Lineage's common shares at a combined purchase price of $0.76 per common share and accompanying comm
$30 Million Upfront With Up to an Additional $36 Million of Aggregate Gross Proceeds Upon the Exercise in Full of Clinical Milestone-linked Common Warrants Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it entered into definitive agreements with certain healthcare focused institutional investors and with Broadwood Partners, L.P. ("Broadwood"), an affiliate of Neal Bradsher, a member of Lineage's board of directors, for the purchase and sale of up to an aggregate of 39,473,688 of Lineage's common shares and accompanying warrants (the "common warrants")
OpRegen® Granted Regenerative Medicine Advanced Therapy (RMAT) Designation From FDA ReSonance™ (ANP1) Preclinical Results Presented at 59th Annual Inner Ear Biology Workshop Added to 2024 Russell 3000® Index Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its third quarter 2024 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update. "We were delighted to see our partners' continued commitment to the OpRegen program, in this instance by seeking
OpRegen® Granted Regenerative Medicine Advanced Therapy (RMAT) Designation From FDA ReSonance™ (ANP1) Preclinical Results Presented at 59th Annual Inner Ear Biology Workshop Added to 2024 Russell 3000® Index Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its third quarter 2024 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update. "We were delighted to see our partners' continued commitment to the OpRegen program, in this instance by seeking
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, November 14, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its third quarter 2024 financial and operating results and to provide a business update. Interested parties may access the conference call on November 14, 2024, by dialing (800) 715-9871 from the U.S. an
24 Month Visual Acuity Benefits from a Single Administration with OpRegen® Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit Supported OpRegen for Geographic Atrophy in Phase 2a Study in Collaboration with Roche and Genentech Initiated Activities Under Recently Established Services Agreement with Genentech to Support Ongoing Development of OpRegen Program OPC1 Clinical Study Start Up Preparations Ongoing Hosted 2nd Annual Spinal Cord Injury Investor Symposium Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its second quarter 2024 fi
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins Clinical Session Expanded to Include Neuralink Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced updates to its 2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS"). The 2nd SCIIS aims to accelerate development in SCI research and treatments by bringing together companies working in the development of treatments for SCI, with regulators, key opinion leaders, persons with lived exp
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact. Dr. Hubbert previously served as Partner and Head of Gates Foundation Venture
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it has appointed George A. Samuel III as Lineage's General Counsel and Corporate Secretary. Mr. Samuel will lead the Company's legal operations, bringing extensive corporate, transactional, intellectual property and commercial expertise which spans nearly 15 years across the life sciences and technology sectors as well as in private practice. "We are pleased to welcome George to our leadership team and look forward to his contributions as we build Lineage into a leading cell therapy and cell transplant comp
424B5 - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
8-K - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
10-Q - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has been added as a member of the broad-market Russell 3000® Index, effective after the U.S. market opens on July 1, 2024, as part of the 2024 Russell indexes reconstitution. The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, 2024, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 33.33 percent decrease over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $1.444 million which beat the analyst consensus estimate of $1.359 million by 6.22 percent. This is a 39.48 percent decrease over sales of $2.386 million the same period last year.
Craig Hallum initiated coverage of Lineage Cell Therapeutics with a rating of Buy and set a new price target of $4.00
Robert W. Baird initiated coverage of Lineage Cell Therapeutics with a rating of Outperform and set a new price target of $5.00
B. Riley Securities initiated coverage of Lineage Cell Therapeutics with a rating of Buy and set a new price target of $4.00